Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gruber

Showing results (241-250 of 355) with videos related to

Pageof 36
Sort By:
Human Vaccines & Immunotherapeutics|September 8, 2017
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trialBhagirath B Solanki, Christine Juergens, Manojkumar B Chopada, et al.
Vaccine|January 1, 1993
Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young childrenP A Piedra, W P Glezen, I Mbawuike, et al.
The Pediatric Infectious Disease Journal|October 19, 2013
13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccineRobert Frenck, Allison Thompson, Shelly Senders, et al.
The Pediatric Infectious Disease Journal|June 3, 2016
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in ChinaFengcai Zhu, Yuemei Hu, Jingxin Li, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 19, 2024
A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infantsYasunori Ishihara, Mitsuru Fukazawa, Shinya Enomoto, et al.
Scientific Reports|July 21, 2023
Identification and validation of fusidic acid and flufenamic acid as inhibitors of SARS-CoV-2 replication using DrugSolver CavitomiXM Hetmann, C Langner, V Durmaz, et al.
The Pediatric Infectious Disease Journal|February 4, 2012
13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safetyFederico Martinón-Torres, Francisco Gimenez-Sanchez, Alejandra Gurtman, et al.
Open Forum Infectious Diseases|May 25, 2026
Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B <i>Clostridioides difficile</i> Vaccine in Adults 50 Years and OlderGretchen Crook, Erik Lamberth, Stephen P Lockhart, et al.
The New England Journal of Medicine|May 15, 1998
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in childrenR B Belshe, P M Mendelman, J Treanor, et al.
Clinical and Vaccine Immunology : CVI|June 29, 2012
Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adultsRobert W Frenck, Alejandra Gurtman, John Rubino, et al.
Pageof 36

Showing results (241-250 of 355) with videos related to

Sort By:
Pageof 36
Human Vaccines & Immunotherapeutics|September 8, 2017
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trialBhagirath B Solanki, Christine Juergens, Manojkumar B Chopada, et al.
Vaccine|January 1, 1993
Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young childrenP A Piedra, W P Glezen, I Mbawuike, et al.
The Pediatric Infectious Disease Journal|October 19, 2013
13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccineRobert Frenck, Allison Thompson, Shelly Senders, et al.
The Pediatric Infectious Disease Journal|June 3, 2016
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in ChinaFengcai Zhu, Yuemei Hu, Jingxin Li, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 19, 2024
A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infantsYasunori Ishihara, Mitsuru Fukazawa, Shinya Enomoto, et al.
Scientific Reports|July 21, 2023
Identification and validation of fusidic acid and flufenamic acid as inhibitors of SARS-CoV-2 replication using DrugSolver CavitomiXM Hetmann, C Langner, V Durmaz, et al.
The Pediatric Infectious Disease Journal|February 4, 2012
13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safetyFederico Martinón-Torres, Francisco Gimenez-Sanchez, Alejandra Gurtman, et al.
Open Forum Infectious Diseases|May 25, 2026
Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B <i>Clostridioides difficile</i> Vaccine in Adults 50 Years and OlderGretchen Crook, Erik Lamberth, Stephen P Lockhart, et al.
The New England Journal of Medicine|May 15, 1998
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in childrenR B Belshe, P M Mendelman, J Treanor, et al.
Clinical and Vaccine Immunology : CVI|June 29, 2012
Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adultsRobert W Frenck, Alejandra Gurtman, John Rubino, et al.
Pageof 36